Guggenheim Reaffirms "Buy" Rating for Eli Lilly and Company (NYSE:LLY)

Key Points

• Guggenheim reaffirmed a Buy rating on Eli Lilly with a $1,183 price target, implying roughly a 20.8% upside from the prior close.
• Strong Q1 results: Lilly beat expectations with $8.55 EPS (vs. $6.97) and $19.8B revenue (up 55.5% YoY), raised FY‑2026 EPS guidance to 35.5–37.0, and has seen multiple analysts lift targets, leaving a consensus of "Moderate Buy" (avg PT $1,217.59).
• Risks remain as FDA‑logged serious liver events tied to Foundayo and competitive pressure from Novo Nordisk’s oral semaglutide could weigh on pricing, market share and near‑term sentiment.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "buy" rating restated by analysts at Guggenheim in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $1,183.00 price target on the stock. Guggenheim's price target would suggest a potential upside of 20.80% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. HSBC cut Eli Lilly and Company from a "hold" rating to a "reduce" rating and dropped their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Argus increased their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Bank of America reduced their price objective on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a "buy" rating for the company in a research note on Friday. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Finally, Truist Financial reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,217.59.

Eli Lilly and Company Price Performance

LLY stock traded up $11.40 during trading hours on Tuesday, hitting $979.33. 441,639 shares of the stock traded hands, compared to its average volume of 3,166,119. The stock has a 50-day simple moving average of $947.05 and a 200 day simple moving average of $987.36. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a market cap of $925.29 billion, a P/E ratio of 34.72, a P/E/G ratio of 1.13 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same quarter last year, the business posted $3.34 earnings per share. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LLY. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp boosted its holdings in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Morgan Stanley boosted its holdings in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after buying an additional 61,851 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term Omvoh (mirikizumab‑mrkz) data show durable disease clearance in ulcerative colitis through four years — this strengthens Lilly’s immunology franchise and supports longer product lifetime value. Lilly Omvoh 4‑Year Data
• Positive Sentiment: Quarterly results: Q1 revenue jumped ~56% to $19.8B driven by Mounjaro/Foundayo demand and management raised guidance — this is the primary bullish catalyst underpinning higher earnings estimates and investor interest. Q1 Results & GLP‑1 Momentum
• Positive Sentiment: Wall Street is pushing targets higher: Barclays raised its LLY target to $1,400 and Wolfe Research reiterated an outperform with a $1,325 target — analyst upgrades amplify buy interest and justify multiple expansion. Barclays Raises Target
• Positive Sentiment: Market share gains: reports show Lilly capturing roughly 60% of the GLP‑1 market and Mounjaro revenue surging — supports sustained top‑line growth and investor conviction in durable market leadership. GLP‑1 Market Share Report
• Neutral Sentiment: Competitive backdrop: Novo Nordisk’s oral semaglutide (Wegovy pill) momentum and earlier launch timing are prompting investor debate; some stories note Novo may face pricing pressure (mixed implications for Lilly’s pricing power and market share). Novo Nordisk Pricing/Competition
• Negative Sentiment: Safety reports: the FDA has logged serious liver events tied to Foundayo and media coverage of a liver‑failure case triggered a noticeable share pullback — safety headlines increase regulatory and reputational risk and are driving short‑term selling pressure. FDA Foundayo Liver Report

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.